We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.8B
AUM Growth
-$577M
Cap. Flow
-$347M
Cap. Flow %
-3.21%
Top 10 Hldgs %
77.46%
Holding
139
New
12
Increased
27
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$517M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$232M
3
DBVT
DBV Technologies
DBVT
+$142M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$66.6M
5
NGNE icon
Neurogene
NGNE
+$63.9M

Top Sells

Rank Stock Value
1
XOMA
Xoma
XOMA
+$57M
2
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$29.2M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.1M
4
OMER icon
Omeros
OMER
+$9.78M
5
DYAX
DYAX CORPORATION
DYAX
+$8.72M

Sector Composition

Rank Sector Weight
1 Healthcare 74.03%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
26
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$24.9M 0.23%
4,350,808
– –
GILD icon
27
Gilead Sciences
GILD
$167B
$24.5M 0.23%
249,995
– –
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$24.4M 0.23%
609,166
+505,000
+485% +$16.5M
ZGNX
29
DELISTED
Zogenix, Inc.
ZGNX
$24.3M 0.22%
1,798,365
+544,794
+43% +$9.83M
ATYR
30
aTyr Pharma
ATYR
$47.2M
$24M 0.22%
166,795
– –
ACGN
31
DELISTED
Aceragen Inc
ACGN
$23.4M 0.22%
51,347
+39
+0.1% +$17.2K
XNPT
32
DELISTED
XENOPORT, INC.
XNPT
$22.6M 0.21%
6,508,622
– –
CPRX
33
DELISTED
Catalyst Pharmaceutical
CPRX
$22M 0.2%
7,335,692
– –
SGMO
34
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$21.2M 0.2%
3,755,876
+524,944
+16% +$4.33M
TGTX icon
35
TG Therapeutics
TGTX
$8.38B
$20.2M 0.19%
2,003,991
– –
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
$19.7M 0.18%
4,310,666
-1,171,839
-21% -$6.95M
CLVS
37
DELISTED
Clovis Oncology, Inc.
CLVS
$18.6M 0.17%
202,630
– –
ALDR
38
DELISTED
Alder Biopharmaceuticals
ALDR
$16.8M 0.16%
513,439
-378,249
-42% -$16.1M
DSCI
39
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$16.3M 0.15%
3,457,841
– –
NVAX icon
40
Novavax
NVAX
$1.22B
$15.5M 0.14%
109,784
+12,500
+13% +$2.8M
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$15M 0.14%
369,276
– –
FOMX
42
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$15M 0.14%
2,046,967
– –
RPRX
43
DELISTED
Repros Therapeutics Inc.
RPRX
$14.5M 0.13%
1,955,944
– –
PRQR icon
44
ProQR Therapeutics
PRQR
$253M
$14.4M 0.13%
988,299
– –
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
$13.8M 0.13%
2,000,000
+476,261
+31% +$3.88M
LRMR icon
46
Larimar Therapeutics
LRMR
$387M
$12.5M 0.12%
32,529
+8,556
+36% +$3.86M
BLUE
47
DELISTED
bluebird bio
BLUE
$12.1M 0.11%
10,893
-772
-7% -$1.41M
RARE icon
48
Ultragenyx Pharmaceutical
RARE
$2.49B
$11.9M 0.11%
123,894
– –
MTEM
49
DELISTED
Molecular Templates, Inc.
MTEM
$11.9M 0.11%
17,730
– –
LJPC
50
DELISTED
La Jolla Pharmaceutical Company
LJPC
$11.4M 0.11%
412,008
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Baker Bros. Advisors held 139 positions worth $10.8B, down 5.1% from $11.4B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $347M in Q3 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Xoma, an estimated $57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in MEDIVATION, INC. worth $28M.

  • Baker Bros. Advisors's largest Q3 2015 buy was MEDIVATION, INC.: 659,752 shares worth $28M.
  • Baker Bros. Advisors added most to Incyte in Q3 2015, an estimated $517M increase.
  • Baker Bros. Advisors's biggest Q3 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $16.1M.
  • Baker Bros. Advisors fully exited Xoma in Q3 2015, selling an estimated $57M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $10.8B portfolio in Q3 2015.
  • Baker Bros. Advisors opened 12 new positions and closed 6 in Q3 2015.
  • Baker Bros. Advisors's portfolio value fell 5.1% quarter-over-quarter to $10.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.